 |
|
|
|
 |
|
|
| Article 1 to 10 out of 10 concerning Micromet Inc.
|
-
Phase 2 Study Confirm High Response Rate of Micromet’s Blinatumomab in Patients with Acute Lymphoblastic Leukemia
(11 Dec 2009)
Micromet, Inc. announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL). The data were presented at the 51st Annual Meeting of the American Society of Hematology ...
-
Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
(03 Dec 2009)
Micromet, Inc. announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.Under the terms ...
-
Micromet Buys Out MedImmune’s Remaining Rights to Blinatumomab
(10 Nov 2009)
Micromet, Inc. announced that it has signed an agreement with MedImmune, LLC to buy out MedImmune’s rights to blinatumomab in North America, and to terminate the collaboration agreement signed in 2003 under which MedImmune had been granted the ...
-
Micromet and Sanofi-aventis Sign Global Collaboration and License Agreement for New Solid Tumor BiTE Antibody
(02 Nov 2009)
Micromet, Inc. and sanofi-aventis announced a global collaboration and license agreement to develop a BiTE(R) antibody against an antigen present at the surface of carcinoma cells. BiTE antibodies are novel therapeutic antibodies that activate a ...
-
Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
(25 Sep 2009)
Micromet, Inc. announced the appointment of Jan Fagerberg, M.D., Ph.D., as Senior Vice President and Chief Medical Officer effective November 1, 2009.Dr. Fagerberg is a board-certified clinical oncologist and has more than 20 years of experience in ...
-
Micromet's BiTE Antibody Blinatumomab Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
(10 Jun 2008)
Micromet, Inc. presented an update of an ongoing phase 1 clinical trial for its BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland. The new data with the ...
-
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110
(28 Apr 2008)
The First BiTE Antibody for Treatment of Solid Tumors
Micromet, Inc. announced the start of a phase 1 clinical trial with its BiTE® antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers. ...
-
Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
(14 Sep 2007)
Micromet, Inc. announced the appointment of Mark Reisenauer as Senior Vice President and Chief Commercial Officer.Mark Reisenauer joins Micromet from Abbott, where he was the General Manager of the Oncology Franchise from 2002 to 2006 and most ...
-
Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize Antibody D93
(20 Mar 2007)
Start of Phase 1 Clinical Trial Planned for the Second Half of This Year
Micromet, Inc. and TRACON Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of products for cancer treatment, announced an agreement granting TRACON exclusive worldwide rights to develop and commercialize ...
-
Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
(14 Feb 2007)
Micromet, Inc. and Morphotek(R) Inc. announced that Morphotek exercised its option under a 2004 agreement to obtain an exclusive worldwide license for an antibody targeting an antigen with potential activity for the treatment of certain cancers, ...
Additional information
Micromet Inc.
Bethesda, MD, USA
Company
|
|
|
|
|
|
Top
